Clinical application of Ga-67 DFO-DAS-fibrinogen.
Scintigraphy with 67Ga-DFO-DAS-fibrinogen (67Ga-fibrinogen) was performed for the positive delineation of thrombi in patients with suspected venous or arterial thrombus formation. Five out of 17 patients showed 67Ga-fibrinogen accumulation corresponding to thrombus formation, as confirmed by other examination including radionuclide venography, contrast angiography, and CT scan. There was some difference in 67Ga-fibrinogen uptake between venous and arterial thrombi. With arterial thrombi, 67Ga-fibrinogen uptake was observed over one year after the appearance of clinical symptoms of dissecting aneurysm and arteriosclerosis obliterans. However, with venous thrombi, 67Ga-fibrinogen uptake occurred less than three weeks after the onset of venous edema. These results may indicate different mechanisms of thrombus organization between venous and arterial thrombi. Further, the thrombi age seems to be an important factor in analyzing the diagnostic accuracy of radioagents used for thrombus scintigraphy.
Department of Nuclear Medicine, Hokkaido University, School of Medicine, Japan.
K
K
Itoh
E
E
Tsukamoto
C
C
Saito
Y
Y
Oguma
M
M
Furudate
D000328:Adult; D000368:Aged; D003676:Deferoxamine; D005260:Female; D005340:Fibrinogen / Q000493:pharmacokinetics; D005710:Gallium Radioisotopes; D006801:Humans; D008297:Male; D008875:Middle Aged; D011877:Radionuclide Imaging; D013213:Starch / Q000031:analogs & derivatives; D013924:Thrombophlebitis / Q000000981:diagnostic imaging; D013927:Thrombosis / Q000000981:diagnostic imaging*; D014018:Tissue Distribution
D005710:Gallium Radioisotopes; D005340:Fibrinogen; D013213:Starch; C012880:dialdehyde starch; D003676:Deferoxamine